If you have type 2 and dont know about GLP-1 heart disease prevention, weight loss, lower A1C, and less hypoglycemia (and many experts associate also associate improved time in range with GLP-1) you can look into this medicine
individual clinical judgment should always guide specific prescribing decisions
A 2022 analysis published in Diabetes, Obesity and Metabolism found that semaglutide treatment was associated with significant improvements in patient-reported energy levels and physical functioning scores, with improvements correlating with both weight loss magnitude and reductions in inflammatory markers (Wilding et al., Diabetes, Obesity and Metabolism, 2022, What GLP-1 Medications Cannot Do for Fatigue This is worth addressing directly, because theres a real risk of patients attributing all their fatigue to weight and expecting GLP-1 medications to fix everything
Consistency matters more than occasional high doses for achieving skin brightening and antioxidant benefits
We expect more details from CMS in May and June, so stay tuned to OAC and OCAN resources for guidance on how providers can navigate prior authorization